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Intensity Conditioning Allogeneic Hematopoietic Stem
Cell Transplantation. A Single-Center Experience
Jose Luis Pin˜ana,1 David Valcarcel,1 Rodrigo Martino,1 Pere Barba,1 Estela Moreno,2
Anna Sureda,1 Monica Vega,1 Julio Delgado,1 Javier Briones,1 Salut Brunet,1 Jorge Sierra1Acute renal failure (ARF) is a life-threatening complication after allogeneic stem cell transplantation
(Allo-HSCT). Identification of ARF risk factors could be useful to develop preventive strategies for patients
at high risk. The goal of this study was to evaluate the incidence and risk factors of ARF after reduced intensity
conditioning Allo-HSCT (Allo-RIC). We included 188 consecutive patients who underwent Allo-RIC in our
center between January 1999 and December 2006. ARF was defined as a decrease of at least 25% in baseline
estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD) equa-
tion. Conditioning consisted of fludarabine (Flu) 150 mg/m2 in combination with busulfan (Bu) 8-10 mg/kg
(n 5 61), melphalan (Mel) 140 mg/m2 (n 5 115), cyclophosphamide (Cy) 120 mg/kg (n 5 7) or low-dose
total-body irradiation (TBI) 2 Gy (n5 5). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclo-
sporine A (CsA) alone (n 5 3) or in addition to methotrexate (MTX; n 5 132) or mycophenolate mofetil
(MMF; n 5 51). The cumulative incidence of ARF at 1 year was 52% (n 5 97 patients) after Allo-RIC.
Most cases (86%) occurred within the first 3 months, and the main cause was the administration of CsA
(71%). The risk factors associated with ARF in multivariate analysis were: administration of MTX (hazard ra-
tio [HR] 1.9, P5.02), more than 3 lines of therapy prior to Allo-RIC (HR 1.8, P5 .01), diabetes mellitus (HR
2.1, P\.01), and GVHD grade III-IV (HR 2.1, P5 .015). In multivariate analysis, ARF was an independent risk
factor for 1-year nonrelapse mortality (NRM) (HR 3, 95% confidence interval [CI]: 1.5-6, P5 .002). Patients
who experienced ARF had lower 1-year overall survival (OS; 53% versus 74%, P\.05). ARF is a frequent
complication in patients after Allo-RIC, and it has a negative impact on outcome. Identification of ARF
risk factors could help to avoid exposure to nephrotoxic drugs during the follow-up in patients at high risk.
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Allo-RICINTRODUCTION
Myeloablative allogeneic hematopoietic stem cell
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6/j.bbmt.2008.10.011matologic toxicity limits the application to young
(\55 years) and fit patients. Reduced-intensity condi-
tioning allogeneic stem cell transplantation (Allo-RIC)
regimens have been designed to reduce toxicity and al-
low stem cell transplantation in the elderly, in patients
with comorbidities, and in those who have been heavily
pretreated. Despite a reduction in conditioning inten-
sity, complications such as graft-versus-host disease
(GVHD), infections, and drug-related toxicity may
still lead to organ injury in these older or debilitated
patients. Organ damage contributes to morbidity and
mortality and, for this reason, remains an important is-
sue in the Allo-RIC setting. Both the intensity of con-
ditioning and also the type of drug combinations may
influence the different patterns of organ damage in
Allo-HSCT [1].
An adequate kidney function is crucial for a man-
agement of life-threatening complications of Allo-
HSCT. In consequence, acute renal failure (ARF)21
22 Biol Blood Marrow Transplant 15:21-29, 2009J. L. Pin˜ana et al.has been associated with higher nonrelapse mortality
(NRM) after myeloablative Allo-HSCT [2-4]. ARF
frequently develops together with other posttransplant
complications such as GVHD, respiratory infections,
drug-related toxicities, and comorbidities, leading to
a multiorgan dysfunction syndrome (MODS) in
a high number of these patients [4-6]. As a result,
ARF requiring dialysis occurs in a high proportion of
these patients and leads to a high mortality rate, rang-
ing from 75% to 100% [7-9].
Although the incidence and severity of ARF after
Allo-RIC seems lower than in myeloablative regimens
[10], incidences of severe ARF of about 30% to 40%
have been reported [11,12]. Furthermore, it seems
that severe ARF is associated with lower survival in
low-dose totaldy irradiation (TBI)-based Allo-RIC
regimens [11,12]. Of note, the impact of ARF in
patients undergoing Allo-RIC may be of highest im-
portance, as these patients usually have poorer perfor-
mance status and other comorbidities.
In viewof these concerns,we assessed renal function
as estimated glomerular filtration rates (GFR) calcu-
lated by modification of diet in renal disease (MDRD)
equation. We report our experience in a large cohort
of patients who underwent Allo-RIC in a single center.
We analyzed ARF incidence and risk factors, and also
the impact of developing ARF on outcome. To the
best of our knowledge, the incidence and risk factors
of ARF after fludarabine (Flu) plus an alkylating agent
(busulfan (Bu) or melphalan (Mel))-based conditioning
Allo-RIC have not been systematically analyzed.PATIENTS AND METHODS
Patients
We included 188 consecutive patients who under-
went Allo-RIC in our institution between January
1999 and December 2006. The reason to use Allo-
RIC was age older than 50 years (n 5 131), the pres-
ence of severe comorbidities (n 5 29), or to have had
undergone prior stem cell transplantation (SCT;
n 5 28). The sources of donor hematopoietic cells
were granulocyte-colony stimulating factor (G-CSF)-
stimulated peripheral blood hematopoietic cells in
most cases (94%) and bone marrow in the remainder
(6%). Patient characteristics are detailed in Table 2.Table 1. Classification of Grades of Severity of ARF
Grade 0 Decrease in estimated GFR < 25% of the
baseline value
Grade 1 Correspond to a less than 2-fold rise in serum
creatinine concentration with a decrease in
estimated GFR >25% but <50% of the
baseline value.
Grade 2 A decrease in estimate GFR >50% of baseline
GFR but not requiring dialysis
Grade 3 grade 2 parameters but requiring dialysis
AFR indicates aute renal failure; GFR, glomerular filtration rate.Conditioning Regimen and GVHD Prophylaxis
We used conditioning regimens as described else-
where [13]. Briefly, Flu 150 mg/m2 was combined with
Bu 8-10 mg/kg for myelogenous neoplasm (n 5 61),
Mel 70-140 mg/m2 for lymphoid neoplasm including
multiple myeloma (MM; n5 115), with Cy clophosfa-
mide (CFM) 120 mg/kg for solid tumors (n 5 7) or
with low-dose TBI 2 Gy for chronic myelogenousleukemia (CML) (n 5 4). One patient with lympho-
blastic lymphoma was treated with CFM and low-dose
TBI as RIC. GVHD prophylaxis consisted of cyclo-
sporine A (CsA) from day 27 in all except 2 patients
who received tacrolimus. The dose was adjusted to
blood levels (between 200 and 300 mg/mL). Metho-
trexate (MTX) (n 5 132) was administered on days
11, 13, and 16 days (10 mg/m2) with folinic acid
rescue. Myophenolate mofetil (MMF) was used
instead of MTX in 51 patients; it was started on day
0 (at least 10 hours after the infusion of progenitors)
at a dose of 1g 3 times daily (15 mg/kg/8 hours).
MMF was continued until day 130 and then tapered.
ARF Assessment
All patients were hospitalized for the procedure.
Daily blood analyses were performed from the day of
admission until discharge. Thereafter, blood analyses
were performed weekly during the first 100 days and
monthly if no complications appeared. GFRwas calcu-
lated by MDRD equation as follows: {GFR (mL/min
per 1.73 m2)5186 * PCr21.154 *age20.203 (* 0.742
if female)} [14,15]. These parameters were measured
on days 29, 115, 130, 160, 1120, 1180, 1360,
and whenever an increase in baseline creatinine was
detected. ARF was classified on the basis of estimated
GFR, as in previous HSCT studies [10-12,16]. ARF
was defined as a decrease of at least 25% of baseline
GFR when creatinine levels rise above the standard
values. ARF gradation is shown in Table 1. ARF
caused by baseline disease progression was excluded
from the analysis, as this was considered a competitive
event. We also excluded ARF in the context of MODS
when it was the last event before death.
Statistical Data
Themain endpoints of the studywere the incidence
of ARF, the identification of its risk factors, and the im-
pact of developing ARF on acute and chronic GVHD
(aGVDH, cGVHD), overall survival (OS), NRM,
and relapse. The probability of OS was estimated
from the time of transplantation using Kaplan-Meier
curves [17], whereas NRM and relapse were calculated
using cumulative incidence estimates, taking into ac-
count the competing risk structure [18,19].Other post-
transplantation outcomes that were calculated using
Table 2. Demographics andBaselineComorbidConditions in
Patients When Categorized by ARF
Variables
ARF at 1
Year (n 5 97)
Without
ARF (n5 91) P Value
Median age in years (range) 55 (18-71) 53 (18-73) .6
Sex Male n, (%) 63 (65) 55 (60) .3
Unrelated Donor, n (%) 19 (19) 13 (14) .5
Underlying disease, n (%) ns
 Acute leukemia/MDS/MPS 31 (32) 38 (41)
 CLL 11 (11) 5 (5)
 NHL 22 (22) 17 (19)
 HD 16 (16) 9 (11)
 MM 11 (11) 18 (20)
 Solid tumors
and others
6 (5) 4 (4)
Number of Prior
therapies, mean ± SD
2.6 ± 1.5 2.4 ± 1.4 .5
Baseline GFR (mL/min/1.73 m2),
mean ± SD
75.6 ± 17 75.4 ± 24 .9
Prior CRD, n (%) 22 (23) 25 (27) .6
HSTC source BM, n (%) 8 (8) 4 (5) .3
Comorbidities, n (%)
 Diabetes 15 (15) 7 (8) .1
 HTA 24 (25) 16 (17) .2
 Cardiomyopathy 17 (17) 11 (12) .3
Advanced disease
status at HSCT, n (%)
70 (72) 61 (67) .5
Mean levels
of CsA (ng/mL) +/2 SD
 During day +15 183 ± 62 184 ± 62 .9
 During day +30 202 ± 61 209 ± 58 .4
Median follow-up
in days (range)
479 (8-2947) 933 (48-2759) .01
Cumulative Incidence of relapse
at 1 year, % (95% CI)
20 (13-29) 26 (18-37) .5
Overall survival
at 1 year
54% 70% .04
ARF indicates acute renal failure; MDS, myelodysplastic syndrome; MPS,
myeloproliferative syndrome; GFR, glomerular filtration rate; CLL,
chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; HD,
Hodgkin disease; MM, multiple myeloma; SD, standard deviation; N,
number; CRD, chronic renal dysfunction; HSCT, hematopoietic stem
cell transplantation; BM, bone marrow source; HTA, arterial hyperten-
sion; CsA, cyclosporine A; GVHD, graft-versus-host disease.
Table 3. Etiology and Grades of ARF
Main Causes of ARF n %
CsA alone 48 50
CsA + sinusoidal obstruction syndrome 3 3
CsA + dehydration 9 9
CsA + GVHD 4 4
CsA + antimicrobial therapy 5 5.2
Total CsA 69 71
Multiorgan failure 3 3.1
Microangiopathy 8 8.2
Dehydration 6 6.2
Adenovirus interstitial nephritis 1 1
Bilateral litiasis obstruction 1 1
Diverse pharmacological toxicity 3 3.1
Undetermined causes 6 6.2
Total 97 100
Grade of ARF n %
Grade 1 84 86
Grade 2 9 10
Grade 3 4 4
CsA indicates cyclosporine A; ARF, acute renal failure; GVHD, graft-
versus-host disease.
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covery, ARF, and GVHD. Univariate analyses of the
association of various clinical risk factors with these lat-
ter posttransplantation outcomeswere calculated using
univariate Cox regression models, whereas the log-
rank test was used forOS [18,19].Multivariate analyses
were performed by Cox proportional hazards regres-
sion, with inclusion of those variables with a value of
P\ .1 in the prior univariate testing. The assumption
of proportional hazards over time was tested for all ex-
planatory covariates using a time-dependent covariate.
To analyze the impact of ARF andGVHD in Allo-RIC
outcome, these variables were entered as time-depen-
dent covariates. Quantitative variables that were found
to have an impact on any outcome were reanalyzed as
categoric variables. Tests of significance were 2-sided,
with significance level of P 5 .05 or less. All statistical
analyses were performed using SPSS version 15.0
(SPSS, Chicago, IL), with the exception of the cumula-
tive incidence analyses, which were carried out with
NCSS 2004 (Number Cruncher Statistical System,Kaysville, UT). If ARF, aGVHD, or cGVHD were
found to have an impact on posttransplantation out-
comes in the final multivariate Cox analysis, plots were
constructed to visually illustrate the effects of each vari-
ables on these outcomes, as described elsewhere [20].RESULTS
Patients Characteristics
No demographic differences were seen between
the 2 groups of patients when categorized as with or
without ARF (Table 2). Comorbidity conditions
were equally distributed between the 2 groups. Sex,
age, diagnosis, disease status, type of donor, type of
transplant, conditioning regimen, and a number of
prior transplants did not differ between patients with
and without ARF.ARF: Incidence, Etiology, and Risk Factors
After amedian follow-upof 49months (range: 4-98)
for survivors, 97 patients developed ARF for a 1-year
cumulative incidence of 52% (95% confidence interval
[CI] 45-60). The median time to the onset of ARF was
31 days (range: 0-320 days). ARF occurred mainly
within the first 3 months after Allo-RIC, as 79 (81%)
of 97 patients developed ARF before day 1100. Most
of the patients (86%) developed grade 1 ARF, 10% de-
veloped grade 2, and only 4% developed grade 3.
The causes of ARF are shown in Table 3. ARF was
directly attributable to CsA in 69 (71%) patients. In
21%of thesepatients, however, the cause ofARFwas at-
tributed to CsA in addition to other transplant-related
complications such as GVHD, absence of fluid intake,
dehydration, and antimicrobial drugs (amphotericin
and aminoglucoside). We did not find any correlation
24 Biol Blood Marrow Transplant 15:21-29, 2009J. L. Pin˜ana et al.between themedianofCsAblood levels at115 and130
days and the development of ARF.
Concerning the risk factors for ARF, demographic
baseline characteristics and severe aGVHD were ana-
lyzed. Univariate and multivariate proportional hazard
ratio models are shown in Table 4. The analyses were
performed at1100 and 1180 days and 1 year after the
Allo-RIC. At day 1100 the variables associated with
higher risk of ARF were: diabetes mellitus (DM) (HR
2.1, CI 95% 1.2-3.8; P 5 .007), having received more
than 3 prior lines of therapy (HR 1.8, CI 95% 1.1-2.9;
P 5 .01), and the use of MTX as GVHD prophylaxis
(HR 1.9, CI 95% 1.1-3.5; P 5 .02). The impact of
MTX and the number of prior therapies were no longer
observed after day 1100. The impact of acute GVHD
(aGVHD) grade III-IV appears as the only risk factor
after day 1100, (HR 2.1, CI 95% 1.2-3.7 and HR 2,
CI 1-3.5 at1180 days and 1 year, respectively,P\ .02).Table 4. Cumulate Incidence and Multivariate Cox Regression Haz
ARF
Variables
Day +100 (N 5 79) D
Univariate
Analysis Cox. Regr
Univaria
Analysi
Cumulative
incidence %
(95% CI) P Value
HR
(95% CI) P Value
Cumulative
incidence %
(95% CI)
Conditioning regimen
 Melphalan 48 (40-59) — 51 (43-62)
 Busulfan+others 25 (16-38) .01 — 37 (31-52)
Acute GVHD prophylaxis
 MTX 46 (38-56) 1.9 (1.1-3.5) .01 49 (41-59)
 Without 9 (4-21) .02 — 40 (29-56)
Donor
 Related 39 (32-48) 44 (37-53)
 Unrelated 47 (33-68) .5 NA 58 (43-79)
Diagnosis
 Myeloid disease 26 (17-39) — 37 (27-51)
 Lymphoid disease 48 (40-59) .01 — 51 (42-62)
Status Disease
 Advanced 45 (37-55) — 49 (41-58)
 Nonadvanced 32 (21-47) .065 — 41 (30-56)
No. therapies before HSCT
 <3 lines 32 (23-48) — 40 (31-52)
 3 or more lines 50 (40-62) .02 1.8 (1.1-2.9) .01 52 (43-64)
Comorbidities
 Diabetes*
- yes 65 (47-91) 2,1 (1.2-3.8) .007 65 (47-91)
- no 38 (31-46) .018 — 44 (37-53)
 HTA
- yes 43 (30-62) 51 (37-69)
- no 40 (33-49) .9 NA 45 (38-54)
 Cardiomyopathy
- yes 37 (23-60) 52 (36-75)
- no 41 (34-50) .7 NA 45 (38-54)
Acute GVHD III-IV
 yes 64 (45-91) — 78 (60-100)
 no 38 (30-47) .048 — 44 (36-53)
ARF indicates acute renal failure; CI, confidence interval; COX. Regr, Cox regr
MTX, methotrexate, No., number; HTA, arterial hypertension.
*DM was defined when patient needed insulin or oral antidiabetic therapy toGVHD
Although severe aGVHD appeared as a risk factor
for ARF, grade II-IV aGVHD occurred in 34% (95%
CI 26-44) of patients who developed previously ARF
compared to 25% (95% CI 17-37) of patients without
ARF (P 5 .1). Patients who developed ARF had a
similar cumulative incidence of cGVHD (72% versus
62%, P 5 .3, respectively). The severity of cGVHD
was not significantly different between the 2 groups
[41% (95% CI 29-58) and 30% (95% CI 19-47), for
patients with and without ARF (p50.2)].NRM
Fifty-five (29%) patients died because of NRM af-
ter a median follow-up of 518 days (range: 8-2947).
Median time to death was 115 days (range: 8-1072).
The 1100, 1180 days, and 1-year cumulativeard Models Analysis of Risk Factors for ARF
ay +180 (N 5 90) 1 Year (N 5 97)
te
s Cox Regr.
Univariate
Analysis Cox Regr.
P Value HR (95% CI) P Value
Cumulative
incidence %
(95% CI) P Value
HR
(95% CI) P Value
— 56 (48-66) —
.053 — 43 (32-58) .087 —
— 53 (45-63)
.1 — 50 (34-62) .26 NA
44 (37-53)
.3 NA 58 (43-79) .3 NA
— 44 (33-58) —
.051 — 56 (47-66) .081 —
54 (46-64)
.2 NA 46 (35-62) .19 NA
— 47 (38-59) —
.08 1.5 (0.97-2.5) .065 57 (47-68) .095 —
1.5 (0.98-3) .08 71 (53-95) —
.037 — 49 (42-58) .035 —
59 (42-58)
.7 NA 50 (43-59) .56 NA
59 (43-81)
.7 NA 50 (43-59) .5 NA
2,1 (1.2-3.7) .015 78 (60-100) 2 (1-3.5) .019
.01 51 (43-61) .02 —
ession hazard model; HR, hazard ratio; GVHD, graft-versus-host disease;
control glycemia before transplant.
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CI: 9-19), 17% (95% CI: 12-23), and 23% (95% CI:
17-29), respectively. The most common causes of
NRM were GVHD and infections (25 patients died
from GVHD and infection, 17 from GVHD without
infection, and 5 from infection without GVHD).
The other deaths were attributed to central nervous
system bleeding (n 5 2), sinusoid obstruction syn-
dromes (n5 2), sudden death (n5 2), progressivemul-
tifocal encephalopathy (n 5 1), and microangiopathy
(n 5 1).
The variables associated with higher NRM at
1100 days and 1 year in univariate analyses are shownTable 5. Cumulate Incidence and Multivariate Cox Regression Haz
Non Rela
Mortality (N
Variables
Day +100
Univariate Analysis Cox Reg
Cumulative
incidence % (95% CI) P Value HR (95% CI)
Conditioning regimen
 Melphalan 8 (4-15)
 Busulfan 10 (5-21) .7 NA
Acute GVHD prophylaxis
 MTX 13 (8-20)
 Without 19 (12-33) .3 NA
Diagnosis
 Myelogenous disease 14 (7-25)
 Lymphoid disease 7 (4-14) .5 NA
Status disease
 Advanced 17 (11-25) —
 Nonadvanced 10 (5-22) .1 —
No. therapies
before Allo-RIC
 5 or <3 lines 7 (4-15) —
 >3 lines 20 (14-31) .02 3.3 (1.4-7.6)
DONOR
 Related 11 (7-17) —
 Unrelated 28 (16-49) .036 —
Comorbidities
 Diabetes
- yes 36 (21-63) 3.2 (1.4-7.3)
- no 11 (7-17) .003 —
 HTA
- Yes 13 (6-28)
- No 14 (10-21) .9 NA
 Cardiomyopathy
- yes 11 (4-31)
- no 14 (10-21) .5 NA
Acute GVHD II-IV
 Yes 34 (24-49) 5.1 (2.3-11.2)
 No 7 (4-13) <.001 —
Chronic GVHD
 Limt/Ext — NA
 No — —
ARF at day +100
 Yes 25 (17-37) 3.4 (1.5-8.1)
 No 5 (2-12) .002 —
ARF at 1-year
 Yes —
 No — NT
CI, indicates confidence interval; Cox. Regr, Cox regression hazard model; HR,
number; HTA, arterial hypertension; Limt, limited; Ext, extended; ARF, acute r
not tested.in Table 5: in multivariate analyses, the variables
associated with NRM were: MTX-GVHD prophy-
laxis (HR of 0.3 [CI 95% 0.2-0.6]) (P 5 .001),
more than 3 prior therapies (HR of 3.3 [CI 95%
1.4-7.6]) (P 5 .001), DM (HR 3.2 [CI 95% 1.4-7.3])
(P 5 .03), aGVHD grade II-IV (HR 5.1 [CI 95%
2.3-11.2] (P 5 .001), and ARF (HR 3.4 [CI 95%
1.5-8.1] (P 5 .002) (Table 5). The effect of ARF,
DM and aGVHD on NRM are shown in figures 1. a,
b and c. The incidence of NRM at 1 year in patients
who developed ARF was 33% compared to 12% for
patients with normal renal function (P5 .001). More-
over, the NRM was even higher in those patients whoard Models analysis of Risk Factors for NRM
pse
RM)
1-year
r. Univariate Analysis Cox Regr.
P Value
Cumulative
incidence % (95% CI) P Value HR (95% CI) P Value
25 (18-34)
19 (12-32) .8 NA
16 (11-24) 0.3 (0.2-0.6) .001
39 (28-54) .003 –
22 (15-35)
24 (18-34) .5 NA
21 (15-30)
21 (13-35) .2 NA
12 (6-20) —
.005 26 (18-36) .059 2.9 (1.5-5.5) .001
19 (13-26) —
43 (30-65) .006 —
.004 45 (29-72) 2.2 (1.1-4.4) .03
20 (15-27) .002 —
22 (13-40)
19 (14-26) .8 NA
25 (13-47)
19 (14-27) .8 NA
.001 46 (35-62) 4.3 (2.3-8.1) <.001
13 (8-20) <.001 —
13 (8-22) —
7 (4-16) .1 —
.005 35 (26-48)
14 (9-22) .002 NT
33 (25-44) 3 (1.5-6) .002
12 (7-21) .001 —
hazard ratio; GVHD, graft-versus-host disease; MTX, methotrevate, No.,
enal failure; RIC, reduced intensity conditioning; NA, not applicable; NT,
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Figure 1. NRMcurves corresponding to (a) ARF development, (b) diabetic status, (c) aGVHD grade II-IV, and (d) according to kidney function recovery.
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45-82) than in those who did (22%, 95% CI 14-34)
(P # .001) (Figure 1.d).
Relapse and OS
The cumulative incidence of relapse at median fol-
low-up of 49 months was 30% (CI 95% 22-40) for the
whole group. Patients who developed ARF had a
1-year cumulative incidence of relapse of 20% (95%
CI 13-29) compared to 26% (95% CI 18-37) of pa-
tients without ARF (P5 .5). The 1-year OS was lower
for patients who developed ARF (54% versus 70%,
P5 .04, Figure 2.a). In addition, OS decreased accord-
ing to the severity of ARF. Patients with ARF grade 2-3
had an OS at 1 year of 33% compared to 59% of pa-
tients with grade 1 and 70% of patients without ARF
(P 5 .003) (Figure 2b).DISCUSSION
The incidence of ARF in this cohort of patients un-
dergoing Allo-RIC was (52%) similar to that observed
in previous reports [2,4,5,7,9,12]. However, most pa-
tients with ARF (86%) developed grade 1 ARF, and
grade 2-3 was observed only in 14% of patients. These
results compares favorably with historic results
with myeloablative regimens [6,10]. Nevertheless, 2
recent studies in nonmyeloablative Allo-HSCT havereported higher incidence of ARF (80%-90%) and
a more severe form (30%-40% grade 2 or greater)
[11,12]; this discrepancy compared to our study could
be explained in part by the substantial differences in
the conditioning regimens, GVHD prophylaxis, and
especially by the much higher targeted dose of CsA
than used in our study.
The main cause of ARF in our study was drug re-
lated (mainly the use of CsA), which has been previ-
ously reported as the main cause of ARF in the
posttransplant setting [21]. By decreasing the CsA
dose, kidney function returned to normal in most of
our patients. As in other studies [2,4,12], we did not
find any relationship between plasma levels of CsA
and the development of ARF. Nevertheless, this could
perhaps be explained by the adjustment of CsA levels
to between 200-300 ng/mL.
Risk factors for the development of ARF had been
delineated by several studies in a myeloablative Allo-
HSCT setting [6,22,23]. However, Allo-RIC differs
widely from myeloablative Allo-HSCT in terms of
conditioning therapy, the patient’s comorbidity pro-
file, and posttransplantation-related complications.
We identified 4 risk factors for ARF: (1) more than 3
lines of chemotherapy prior to Allo-RIC, (2) the use
of MTX as GVHD prophylaxis regimen, (3) aGVHD
grade III-IV, and (4) DM. MTX and number of prior
chemotherapy have not been reported previously as
risk factors for ARF in Allo-RIC. Heavily pretreated
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Figure 2. KM 1-year OS curves (a) according to ARF and (b) according
to ARF grades.
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though this may have been subclinical in the evaluation
before SCT, it could predispose these patients to
develop ARF in subsequent exposure to nephrotoxic
drugs. MTX is a well-known nephrotoxic drug [24],
even when it is used at low doses, and it is not surprising
that it can be related to ARF in patients undergoing
Allo-RIC. The absence of prior reports regarding the
relationship between MTX and ARF in nonmyeloabla-
tive transplants seems to be related to the use of MMF
instead of MTX as GVHD prophylaxis [9,11,12].
The relationship between ARF and cGVHD has
been described by Parikh et al. [11], who showed that
the development of ARFwas associated with higher in-
cidence of cGVHD, which may be because of the ta-
pering of CsA [25] in those patients who develop
ARF. In our study, as in the study by Kersting et al.
[12], we found that the development of severe aGVHD
was a risk factor for ARF, which could be related to the
use of nephrotoxic drugs and the dehydration. Proba-
bly the relationship is bidirectional, and both compli-
cations are closely linked.
The impact of DM in the allo-HSCT is contro-
versial. One study has shown that preexistingdiabetes is associated, albeit weakly, with ARF [10],
whereas a recent multivariate analysis by Kersting
et al. [12], reported that the absence of preexisting
vascular disease (including diabetes, myocardial
infarction, angina pectoris, and cerebrovascular
event) was an independent risk factor for the devel-
opment of ARF. The authors considered that these
controversial results could be explained by the fact
that physicians monitored the CsA levels and creati-
nine more closely in this vulnerable group of
patients. Moreover, in a recent study with patients
that underwent an Allo-RIC, DM was not associated
with ARF [9]. and the authors supported the use of
RIC regimens for diabetic patients who were not
eligible for myeloablative transplantation because of
preexisting impaired renal function.
Our results, however, indicated that DM was
a strong factor associated with the development of
ARF throughout the transplant, although the signifi-
cance is lower after day 1100. Diabetic nephropathy
is a leading cause of end-stage renal disease and CsA,
which is the main cause of renal impairment in
HSCT, has been associated with kidney impairment
in diabetic patients [26]. It is also important to empha-
size that CsA induces an abnormal glucose metabolism
by decreasing insulin release and inducing peripheral
insulin resistance in diabetic patients undergoing kid-
ney transplantation [27]. Moreover, steroids com-
monly used in this setting could also impair glucose
metabolism and may also lead to renal damage. There-
fore, it is highly probable that diabetic status in con-
junction with kidney (CsA) and glucose metabolism
(steroids) injuries could have a synergic effect on renal
damage. Taking all of this into account, it seems very
important to closely monitor diabetic patients and, if
possible, to avoid other known toxic drugs such as
MTX or nonsteroid anti-inflammatory drugs. There
is some evidence in heart transplantation that
substituting CsA for sirolimus improves renal recovery
compared to lower dose CsA plus sirolimus [28].
Other studies on autologous and allogeneic HSCT
have found that the need for mechanical ventilation
(MV) is the strongest risk factor associated with ARF
and implies a high mortality rate [9,29]. However,
MV, especially in the context of respiratory infections,
is usually accompanied by exposure to antimicrobial
drugs with a high nephrotoxic profile, leading to kid-
ney failure. This setting often leads to dysfunction of
other organs (liver, heart, bone marrow) and subse-
quent MODS. The association between MV and
ARF is controversial in the above-mentioned studies,
as it was not reported how many patients who needed
MV had respiratory failure in the context of MODS.
As well, liver failure has also been associated with se-
vere ARF in myeloablative Allo-HSCT [22], without
data about how many patients with liver dysfunction
had MODS. Because MODS is a well-characterized
28 Biol Blood Marrow Transplant 15:21-29, 2009J. L. Pin˜ana et al.and unified syndrome that involves 2 or more organ
systems [30], we did not consider each organ failure
separately in the analysis. We considered MODS as
a single entity because of the concomitant failure of
multiple interreliant organ systems.
Although the development of an RIC regimen has
allowed patients who are ineligible for standard Allo-
HSCT to benefit from allogeneic therapy, NRM re-
mains a significant obstacle to success with Allo-RIC.
Our study showed that the development of ARF was
strongly related to higher NRM and lower OS. These
results are in line with preceding reports on myeloa-
blative and RIC regimens [2,11]. All these reports en-
hance the suggestion that renal function is critical not
only in Allo-HSCT but also in Allo-RIC patients.
Moreover, as patients who undergo Allo-RIC are older
and have other comorbidities, they are more vulnera-
ble to complications. In our study, we also identified
other variables as independent risk factors for NRM.
These were DM, aGHVD, no MTX as GVHD pro-
phylaxis, and more than 3 lines of chemotherapy be-
fore Allo-RIC. In our study, MTX appears to be
protective against NRM, whereas it is associated with
increased ARF; this apparent contradiction can be ex-
plained by the fact that MTX shows collinearity with
an HLA matched sibling donor, whereas MMF show
collinearity with unrelated donors (URD). One hun-
dred twenty-five (80%) of 156 patients with HLA fa-
miliar donor received MTX as GVHD prophylaxis
by only 7 (22%) of 32 patients with URD (P \
.0001). In our study, URD had a higher cumulative
incidence NRM compared to an HLAmatched sibling
donor: (43% [95% CI 30-65]) veresus (19% [95% CI
13-26]), respectively (P 5 .006).
In conclusion, we found that the incidence of severe
ARF seems to be lower in Fludarabine plus alkylating
agent-based RIC than myeloablative regimens. Despite
this, ARF remains a life-threatening complication in
this setting. DM, the use of MTX, having received
more than 3 lines of treatments before transplant, and
the development of severe aGVHD are the main risk
factors associated with ARF in the patients undergoing
Allo-RIC. The development of preventive strategies to
avoid ARF is required in these patients.ACKNOWLEDGMENTS
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